Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Harvard Business School
Boehringer Ingelheim
Express Scripts
Colorcon
Merck
Johnson and Johnson

Last Updated: November 12, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Aleglitazar

See Plans and Pricing

« Back to Dashboard

What is the drug development status for Aleglitazar?

Aleglitazar is an investigational drug.

There have been 22 clinical trials for Aleglitazar. The most recent clinical trial was a Phase 3 trial, which was initiated on October 1st 2012.

The most common disease conditions in clinical trials are Diabetes Mellitus, Type 2, Diabetes Mellitus, and Coronary Disease. The leading clinical trial sponsors are Hoffmann-La Roche and [disabled in preview].

There are forty-three US patents protecting this investigational drug and three hundred and forty-three international patents.

Recent Clinical Trials for Aleglitazar
TitleSponsorPhase
A Study of Alegitazar in Patients With Type 2 Diabetes And Chronic Kidney Disease (Alerenal Study)Hoffmann-La RochePhase 3
A Study of Aleglitazar in Monotherapy in Patients With Type 2 Diabetes Mellitus Who Are Drug-Naïve to Anti-Hyperglycemic TherapyHoffmann-La RochePhase 3
A Study of Aleglitazar in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Metformin MonotherapyHoffmann-La RochePhase 3

See all Aleglitazar clinical trials

Clinical Trial Summary for Aleglitazar

Top disease conditions for Aleglitazar
Top clinical trial sponsors for Aleglitazar

See all Aleglitazar clinical trials

US Patents for Aleglitazar

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Aleglitazar   Start Trial Oxazole derivatives Hoffmann-La Roche Inc. (Nutley, NJ)   Start Trial
Aleglitazar   Start Trial Process for the production of chiral propionic acid derivatives Hoffman-La Roche Inc. (Nutley, NJ)   Start Trial
Aleglitazar   Start Trial Process for the production of chiral propionic acid derivatives Hoffmann-La Roche Inc. (Nutley, NJ)   Start Trial
Aleglitazar   Start Trial Methods for treating myelodysplastic syndrome with a human interleukin-3-diphtheria toxin conjugate Scott and White Memorial Hospital (Temple, TX) Scott, Sherwood and Brindley Foundation (Temple, TX)   Start Trial
Aleglitazar   Start Trial Nanoparticles for protein drug delivery GP Medical, Inc. (Newport Beach, CA) National Tsing Hua University (Hsinschu, TW)   Start Trial
Aleglitazar   Start Trial Nanoparticles for protein drug delivery GP Medical, Inc. (Newport Beach, CA) National Tsing Hua University (Hsinchu, TW)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Aleglitazar

Drugname Country Document Number Estimated Expiration Related US Patent
Aleglitazar Argentina 035892 2021-05-15   Start Trial
Aleglitazar Austria 327753 2021-05-15   Start Trial
Aleglitazar Australia 2002342244 2021-05-15   Start Trial
Aleglitazar Bulgaria 108362 2021-05-15   Start Trial
Aleglitazar Bulgaria 66316 2021-05-15   Start Trial
Aleglitazar Brazil 0209821 2021-05-15   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Boehringer Ingelheim
Harvard Business School
Merck
Express Scripts
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.